Abstract
Methadone maintenance treatment (MMT) in the United States, and particularly the clinic system of distribution, is often criticized as punitive, over-regulated, and misaligned to the needs of many patients. However, changes to the regulations that COVID-19 caused may have provided an opportunity for improving service. This commentary uses literature and my own experience to provide a brief description of how MMT programs responded to the threat of Covid-19 and how such responses fit into the larger context of attempts to reform treatment. It discusses, in particular, opportunities for liberalizing “take-home” doses and implementing office-based MMT.
All Keywords
【저자키워드】 COVID-19, harm reduction, Take-home doses, Methadone maintenance treatment (MMT), Medication assisted treatment (MAT), Methadone clinics, 【초록키워드】 Treatment, Methadone, response, distribution, change, patients, dose, Regulation, The United States, caused, provided, 【제목키워드】 Treatment, Methadone, age,
【저자키워드】 COVID-19, harm reduction, Take-home doses, Methadone maintenance treatment (MMT), Medication assisted treatment (MAT), Methadone clinics, 【초록키워드】 Treatment, Methadone, response, distribution, change, patients, dose, Regulation, The United States, caused, provided, 【제목키워드】 Treatment, Methadone, age,